Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection
Open Access
- 6 July 2007
- journal article
- Published by Wiley in BJOG: An International Journal of Obstetrics and Gynaecology
- Vol. 114 (9), 1113-1121
- https://doi.org/10.1111/j.1471-0528.2007.01308.x
Abstract
Objectives To report early experience with treatment of intrauterine cytomegalovirus (CMV) infection using maternal oral administration of valaciclovir (VACV). Design Observational study of fetuses infected with CMV with or without treatment with valaciclovir. Population Pregnancies with confirmed fetal CMV infection were treated with oral VACV (8 g/day). Main outcome measures Fetal viral load and drug concentration were monitored in amniotic fluid and in fetal blood. Data on the course and outcome of a group of untreated symptomatic fetuses infected with CMV are also reported. Results Therapeutic concentrations were achieved in maternal and fetal bloods. The viral load in the fetal blood (VLFB) decreased significantly after 1–12 weeks of treatment (Wilcoxon paired test P= 0.02). Twenty pregnancies including 21 fetuses were treated at 28 weeks (median, range: 22–34) for 7 weeks (median, range: 1–12). Ten infants were developing normally at between 1 and 5 years of age. Two infants (both aged 2 years) had severe isolated unilateral deafness. One neonate presented with microcephaly and severe deafness but was also diagnosed with incontinentia pigmenti. Six out of seven cases that eventually required termination of pregnancy (TOP) had evidence of in utero progression of the disease with worsening cerebral lesions. One fetus died in utero. The outcome of 14/24 (58.3%) untreated symptomatic infected fetuses was poor with either TOP, intrauterine fetal demise or severe congenital infection disease of the neonate; the remaining ten infants were healthy at follow up. Conclusion Maternal oral administration of VACV leads to therapeutic concentrations in the maternal and fetal compartments, with a decrease in VLFB. Our results suggest that in cases where TOP is declined, a randomised controlled trial to study this treatment option further is indicated.Keywords
This publication has 39 references indexed in Scilit:
- Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunityThe Journal of Pediatrics, 2006
- P09.01: Correlations between ultrasound and fetal haematological parameters in 67 fetuses infected with cytomegalovirus (CMV)Ultrasound in Obstetrics & Gynecology, 2005
- Congenital Cytomegalovirus Infection: Association between Virus Burden in Infancy and Hearing LossThe Journal of Pediatrics, 2005
- Cytomegalovirus (CMV) glycoprotein B genotype and CMV DNA load in the amniotic fluid of infected fetusesPrenatal Diagnosis, 2004
- Hyperechogenic bowel in the second trimester fetus: a reviewPrenatal Diagnosis, 2000
- Prenatal diagnosis of fetal cytomegalovirus infection after primary or recurrent maternal infectionObstetrics & Gynecology, 1999
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationThe New England Journal of Medicine, 1999
- The megalovirusUltrasound in Obstetrics & Gynecology, 1998
- Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacyAntiviral Research, 1995
- Ganciclovir therapy for symptomatic congenital cytomegalovirus infection in infants: A two-regimen experienceThe Journal of Pediatrics, 1994